Treatment of Splenic Marginal Zone Lymphoma Without Hepatitis C When Therapy Is Indicated
For patients with splenic marginal zone lymphoma (SMZL) who do not have hepatitis C infection,
the choice to initiate active treatment is guided by the presence of specific clinical indications.
This page summarises the key decision points; the complete structured protocol is available below.
Clinical Scenario
This first-line protocol applies to SMZL patients without hepatitis C infection who have developed
an indication for treatment. Recognised indications include:
- Constitutional (B) symptoms
- Progressive cytopenia
- Symptomatic splenomegaly
- Bulky lymphadenopathy
- Autoimmune phenomena
- Compromised vital organs or bulky disease
Treatment Approach (partial overview)
Symptomatic patients are candidates for systemic therapy. Anti-CD20 antibody-based strategies —
used as monotherapy or incorporated into immunochemotherapy — are central to management,
with surgical and local approaches also available depending on patient fitness and disease characteristics.
Full regimen options, patient-selection criteria, sequencing, and response-adapted strategy are in the complete protocol.
Response Goals
A complete response requires all of the following:
- Resolution of splenomegaly (spleen length <13 cm)
- Resolution of cytopenias with normalisation of haemoglobin, platelets, and neutrophils
- No clonal B-cell population detectable in peripheral blood
- No evidence of bone marrow infiltration
References
DOI: 10.1111/bjh.19064
- The main criteria for treatment include constitutional symptoms, symptomatic or progressive splenomegaly, bulky lymphadenopathy, autoimmune phenomena and progressive cytopenias, as shown in Table 9.
- SMZL patients with hepatitis C infection should receive up-front anti-viral therapy.
- Systemic therapy options for symptomatic patients include rituximab monotherapy, immunochemotherapy and splenectomy, based on a few small prospective phase II trials.
View source ↗